Sarepta Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Sarepta Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About SRPT

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA. 

CEO
Douglas S. Ingram
CEODouglas S. Ingram
Employees
1,372
Employees1,372
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
1980
Founded1980
Employees
1,372
Employees1,372

SRPT Key Statistics

Market cap
2.39B
Market cap2.39B
Price-Earnings ratio
-7.89
Price-Earnings ratio-7.89
Dividend yield
Dividend yield
Average volume
3.46M
Average volume3.46M
High today
$23.00
High today$23.00
Low today
$21.45
Low today$21.45
Open price
$21.56
Open price$21.56
Volume
3.40M
Volume3.40M
52 Week high
$131.31
52 Week high$131.31
52 Week low
$10.42
52 Week low$10.42

Stock Snapshot

With a market cap of 2.39B, Sarepta Therapeutics(SRPT) trades at $22.73. The stock has a price-to-earnings ratio of -7.89.

During the trading session on 2025-12-04, Sarepta Therapeutics(SRPT) shares reached a daily high of $23.00 and a low of $21.45. At a current price of $22.73, the stock is +6.0% higher than the low and still -1.2% under the high.

Trading volume for Sarepta Therapeutics(SRPT) stock has reached 3.4M, versus its average volume of 3.46M.

The stock's 52-week range extends from a low of $10.42 to a high of $131.31.

The stock's 52-week range extends from a low of $10.42 to a high of $131.31.

SRPT News

Simply Wall St 17h
There's No Escaping Sarepta Therapeutics, Inc.'s Muted Revenues Despite A 35% Share Price Rise

Sarepta Therapeutics, Inc. ( ) shareholders would be excited to see that the share price has had a great month, posting a 35% gain and recovering from prior wea...

There's No Escaping Sarepta Therapeutics, Inc.'s Muted Revenues Despite A 35% Share Price Rise
Simply Wall St 3d
Did FDA Green Light for ELEVIDYS and Pipeline Progress Just Shift Sarepta Therapeutics' Narrative?

In late November 2025, Sarepta Therapeutics announced two major developments: FDA approval to begin dosing non-ambulant Duchenne muscular dystrophy patients wit...

Did FDA Green Light for ELEVIDYS and Pipeline Progress Just Shift Sarepta Therapeutics' Narrative?

Analyst ratings

56%

of 25 ratings
Buy
24%
Hold
56%
Sell
20%

People also own

Based on the portfolios of people who own SRPT. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.